@article{cb1bcdc25ea24af6a1ca694959614383,
title = "CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis",
abstract = "Intake of hemoglobin by the hemoglobin-haptoglobin receptor CD163 leads to a distinct alternative non-foam cell antiinflammatory macrophage phenotype that was previously considered atheroprotective. Here, we reveal an unexpected but important pathogenic role for these macrophages in atherosclerosis. Using human atherosclerotic samples, cultured cells, and a mouse model of advanced atherosclerosis, we investigated the role of intraplaque hemorrhage on macrophage function with respect to angiogenesis, vascular permeability, inflammation, and plaque progression. In human atherosclerotic lesions, CD163+ macrophages were associated with plaque progression, microvascularity, and a high level of HIF1α and VEGF-A expression. We observed irregular vascular endothelial cadherin in intraplaque microvessels surrounded by CD163+ macrophages. Within these cells, activation of HIF1α via inhibition of prolyl hydroxylases promoted VEGF-mediated increases in intraplaque angiogenesis, vascular permeability, and inflammatory cell recruitment. CD163+ macrophages increased intraplaque endothelial VCAM expression and plaque inflammation. Subjects with homozygous minor alleles of the SNP rs7136716 had elevated microvessel density, increased expression of CD163 in ruptured coronary plaques, and a higher risk of myocardial infarction and coronary heart disease in population cohorts. Thus, our findings highlight a nonlipid-driven mechanism by which alternative macrophages promote plaque angiogenesis, leakiness, inflammation, and progression via the CD163/HIF1α/VEGF-A pathway.",
author = "Liang Guo and Hirokuni Akahori and Emanuel Harari and Smith, {Samantha L.} and Rohini Polavarapu and Vinit Karmali and Fumiyuki Otsuka and Gannon, {Rachel L.} and Braumann, {Ryan E.} and Dickinson, {Megan H.} and Anuj Gupta and Jenkins, {Audrey L.} and Lipinski, {Michael J.} and Johoon Kim and Peter Chhour and {De Vries}, {Paul S.} and Hiroyuki Jinnouchi and Robert Kutys and Hiroyoshi Mori and Kutyna, {Matthew D.} and Sho Torii and Atsushi Sakamoto and Choi, {Cheol Ung} and Qi Cheng and Grove, {Megan L.} and Sawan, {Mariem A.} and Yin Zhang and Yihai Cao and Kolodgie, {Frank D.} and Cormode, {David P.} and Arking, {Dan E.} and Eric Boerwinkle and Morrison, {Alanna C.} and Jeanette Erdmann and Nona Sotoodehnia and Renu Virmani and Finn, {Aloke V.}",
note = "Funding Information: This study is supported by the CVPath Institute; the Woodruff Sciences Health Center at Emory University; and the Car- lyle Fraser Heart Center at Emory Hospital Midtown. CUC is supported by a grant from the CardioVascular Research Foundation (CVRF) of Korea. Genotyping of the CVPath cohort was supported by the National Heart, Lung, and Blood Institute (NHLBI) (HL111089, to NS). The ARIC study was funded in whole or in part with federal funds from the NHLBI, NIH, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for “Building on GWAS for NHLBI Diseases: the US CHARGE Consortium” was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). The authors thank Daniel McVicar and Marieli Gonzalez-Cotto (National Cancer Institute) and Nicholas Leeper (Stanford University) for helpful discussions and Lila Adams (CVPath Institute) for technical assistance with immunostaining. Funding Information: This study is supported by the CVPath Institute; the Woodruff Sciences Health Center at Emory University; and the Carlyle Fraser Heart Center at Emory Hospital Midtown. CUC is supported by a grant from the CardioVascular Research Foundation (CVRF) of Korea. Genotyping of the CVPath cohort was supported by the National Heart Lung, and Blood Institute (NHLBI) (HL111089, to NS). The ARIC study was funded in whole or in part with federal funds from the NHLBI, NIH, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for {"}Building on GWAS for NHLBI Diseases: the US CHARGE Consortium{"} was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). The authors thank Daniel McVicar and Marieli Gonzalez-Cotto (National Cancer Institute) and Nicholas Leeper (Stanford University) for helpful discussions and Lila Adams (CVPath Institute) for technical assistance with immunostaining. Publisher Copyright: {\textcopyright} 2018 Blackwell Publishing Ltd. All rights reserved.",
year = "2018",
month = mar,
day = "1",
doi = "10.1172/JCI93025",
language = "English",
volume = "128",
pages = "1106--1124",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",
}